According to the Wall Street Journal, AbbVie is in advanced discussions to purchase Revolution Medicines, a cancer-focused biotechnology company valued at approximately $16 billion. The proposed transaction is expected to bolster AbbVie's oncology pipeline, adding Revolution’s KRAS inhibitor candidates that have shown promising Phase II clinical data with response rates exceeding 40% in non-small cell lung cancer. Sources indicate that AbbVie’s deal structure may include a mix of cash and equity consideration, with due diligence currently underway and a potential agreement announcement targeted for the first quarter of 2026.

AbbVie will release its full-year and fourth-quarter 2025 financial results on February 4, 2026, before the U.S. equity market opens, and host a live webcast at 8 a.m. Central Time. Investors can access the call through AbbVie’s Investor Relations website, where an archived replay will be available later that day. Analysts will be watching for trends in the immunology franchise—particularly the performance of the rheumatoid arthritis therapy, which delivered 12% year-over-year revenue growth in Q3 2025—and any updated 2026 guidance for both sales and research-and-development expenditures.

AbbVie shares have demonstrated significant rally potential, having achieved a more than 50% increase over a two-month span in 2020 and recording seven separate rallies exceeding 30% within similar intervals, notably in 2017 and 2024. These breakout episodes were frequently driven by positive clinical trial readouts and strategic deal announcements, suggesting that investor sentiment remains highly responsive to both pipeline developments and merger-related news flow.